Levi & Korsinsky notifies investors that it has commenced an investigation into Tvardi Therapeutics, Inc. (NASDAQ: TVRD) concerning potential violations of the federal securities laws.
On October 13, 2025, Tvardi reported data from its Phase 2 REVERT study testing its STAT3 inhibitor drug, TTI-101, to treat patients with idiopathic pulmonary fibrosis (IPF). The company reported that “the study did not meet its goals,” as the “[p]reliminary analysis of exploratory efficacy showed no statistically significant differences between placebo and treatment arms.” Management also highlighted significant discontinuation rates of more than 56% in both treatment arms compared to only 10.3% in the placebo group. Following this news, Tvardi’s stock price fell by $34.91 per share to close at $6.69 per share.
If you suffered a loss on your Tvardi Therapeutics, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





